Synthesis and Development of Silicone-Based Drug-Eluting Contact Lens Using Polysaccharide-Silicone Core-Shell Nanocapsules with Combined Functions
|關鍵字:||雙性幾丁聚醣複合物;自組裝;藥物釋放;矽水膠;奈米載體;藥物釋放;Amphiphlic hybrid chitosan (CHC);self-assembly;controlled drug delivery;silicone hydrogel;nanocapsule|
之雙性幾丁聚醣(CHC) ， 同時加以改質成新的無機- 有機雙性混成分子
合性水膠材料), 顯示可控制的藥物釋放行為, 突顯本計畫之高度可行性。本研
Ophthalmic solutions are generally administrated via oral or eye drops. In terms of oral, drugs were largely consumed by metabolism, resulting in poor therapeutic efficacy. In terms of eye drops, only 1% to 7% of the dose delivered from eye drop is absorbed by the eye. Therefore, it is technically and industrially important if a contact lens capable of eluting therapeutic agents in a wide variety of manners to meet clinical demands, which renders not only high water uptake, but also imparts diverse therapeutic ability. Combining a novel drug nanocarrier developed recently in this lab, namely amphiphilic hybrid chitosan (CHC), and commercial available silicone contact lens material, giving a composite material, we intend in this proposal to employ the CHC as drug carrier to form a drug-eluting contact lens, a topic that has been raised a huge attention in medical device worldwide in recent decade, but seems very lean and little developed in Taiwan. The CHC hybrid macromolecule has been confirmed capable of self-assembling to hollow nanocapsules with controllable size and hydrophobicity (NSC-98-2113-M-009-004). In our early evaluation, this hybrid molecule appears to show excellent compatibility to the silicone hydrogels (provided from cooperative partner of this proposal) and it also demonstrated a high feasibility of drug elution. On these bases, we believe an in-depth understanding the chemical, physical, and biomedical fundamentals of this system is critically needed and urgent, which is aimed to trigger the development of medical-grade contact lenses.